Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $12.5 million.

  • Crinetics Pharmaceuticals' Interest & Investment Income rose 1397.42% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year increase of 6336.97%. This contributed to the annual value of $41.4 million for FY2024, which is 20838.79% up from last year.
  • Crinetics Pharmaceuticals' Interest & Investment Income amounted to $12.5 million in Q3 2025, which was up 1397.42% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income registered a high of $14.8 million during Q1 2025, and its lowest value of $24000.0 during Q3 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.3 million (2023), whereas its average is $5.6 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Interest & Investment Income crashed by 9460.43% in 2021, and later soared by 615000.0% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income (Quarter) stood at $80000.0 in 2021, then soared by 2280.0% to $1.9 million in 2022, then skyrocketed by 253.05% to $6.7 million in 2023, then surged by 113.75% to $14.4 million in 2024, then dropped by 12.69% to $12.5 million in 2025.
  • Its last three reported values are $12.5 million in Q3 2025, $13.5 million for Q2 2025, and $14.8 million during Q1 2025.